Edgar Filing: JORDAN WADIH - Form 4

Form 4	DIH										
July 02, 2009	Л								OMB A	PPROVAL	
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549								N OMB Number:	3235-0287	7	
Check this if no longe subject to Section 16.	r STATEN	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES							Expires: Estimated burden hou	•	
									response	•	5
(Print or Type Re	esponses)										
1. Name and Address of Reporting Person <u>*</u> JORDAN WADIH			2. Issuer Name and Ticker or Trading Symbol				-	5. Relationship of Reporting Person(s) to Issuer			
			ANTIGENICS INC /DE/ [AGEN]				ENJ	(Check all applicable)			
(Last) (First) (Middle) C/O ANTIGENICS INC., 162 FIFTH AVE., SUITE 900			3. Date of Earliest Transaction (Month/Day/Year) 07/01/2009					X_ Director 10% Owner Officer (give title Other (specify below) below)			
				. If Amendment, Date Original iled(Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 				
NEW YORK	, NY 10010							Person	More than One R	eporting	
(City)	(State)	(Zip)	Tabl	le I - Non-l	Derivativ	ve Secur	ities A	Acquired, Disposed	of, or Beneficia	lly Owned	
	. Transaction Date Month/Day/Year)	2A. Deemed Execution Da any (Month/Day/		3. Transactic Code (Instr. 8)		ed (A) or ed of (D))	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V			Price				
Reminder: Repor	t on a separate line	e for each class	s of secu	irities bene	Pers info requ	sons wi rmatior uired to	ho res n cont resp	or indirectly. spond to the colle tained in this forn ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	

displays a curren number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	8.1
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities	De
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	Sec

Edgar Filing: JORDAN WADIH - Form 4

(Instr. 3)	Price of Derivative Security	(Month/Day/Yea	ar) (Instr. 8)	str. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)				(Ir	
			Code V	(A) (D)) Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Deferred Shares (1)	<u>(1)</u>	07/01/2009	А	9,333.5	<u>(1)</u>	<u>(1)</u>	Common Stock	9,333.5	\$

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
JORDAN WADIH C/O ANTIGENICS INC. 162 FIFTH AVE., SUITE 900 NEW YORK, NY 10010	Х						
Signatures							
Christine M. Klaskin, by Power Attorney	of	07/	02/2009				

<u>**</u>Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Acquired under the Antigenics Directors' Deferred Compensation Plan, as amended. Deferred Shares represent an equal amount of shares(1) of the Company's common stock to be distributed with the terms of the Plan, typically once the director ceases to serve as a director of the Company.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.